VEGF Plasmid

The VEGF plasmid therapy involves delivering a plasmid DNA encoding for Vascular Endothelial Growth Factor (VEGF), a protein that promotes angiogenesis, the formation of new blood vessels. This mechanism exploits the body’s natural processes to enhance blood supply to tissues that are ischemic or have reduced blood flow.

VEGF is known to play a critical role in both physiological and pathological angiogenesis. On a molecular level, once the VEGF plasmid is delivered into target cells, it utilizes the host cell's machinery to produce VEGF protein. This protein then interacts with specific receptors on the surface of endothelial cells, such as VEGFR-1 and VEGFR-2, which are primarily involved in the proliferation and migration of these cells, leading to new blood vessel formation.

Delivery Systems:

• Use of nanoparticles: The study published in the International Journal of Pharmaceutics (PMID: 42508511) discusses using PLGA nanoparticles to deliver VEGF plasmids. These nanoparticles help target and release the plasmid into bone tissues, which may be beneficial for treating conditions like osteoporosis by enhancing local blood supply and supporting bone regeneration.

• Core-shell fibrous threads: Another approach detailed in Biomedical Materials (PMID: 42372784) is using fibrous threads loaded with VEGF plasmid polyplexes. This method facilitates sustained gene delivery, ensuring continuous production of VEGF at levels that exceed a therapeutic threshold, especially useful in chronic ischemic conditions.

Clinical Applications:

• Lower Extremity Ischemia: As discussed in Cells (PMID: 42346131), angiogenic gene therapy using VEGF plasmids has been tested experimentally and clinically to improve blood supply in ischemic lower extremities, addressing issues like intermittent claudication as shown in clinical trial NCT00080392.

• Cardiac Angiogenesis: The NCT00620217 trial examines using the VEGF-A165/bFGF plasmid in patients with coronary artery disease. By enhancing angiogenesis, the therapy might offer an option for patients not eligible for other revascularization procedures.

In summary, VEGF plasmid therapy primarily acts by stimulating angiogenesis at a molecular level, addressing conditions with inadequate blood flow or tissue damage by leveraging targeted delivery systems to enhance therapeutic outcomes.

Disclaimer: This content is for informational purposes only and not intended as personalized medical advice. Always consult a healthcare professional for medical concerns.

VEGF (Vascular Endothelial Growth Factor) plasmids are utilized in various clinical contexts primarily focused on promoting angiogenesis, which is the formation of new blood vessels. This therapeutic approach aims to improve blood flow and tissue healing in several conditions.

1. Osteoporosis Therapy: A study published in the International Journal of Pharmaceutics discusses the use of bone-targeted delivery of VEGF and BMP2 plasmids for treating osteoporosis. The delivery via nanoparticles suggests potential benefits in promoting bone regeneration and enhancing bone density through angiogenesis and osteogenesis.

2. Lower Extremity Ischemia: According to a paper in Cells, VEGF gene therapy has made experimental and clinical advances in treating lower extremity ischemia. This condition, characterized by reduced blood flow to the extremities, may benefit from enhanced vascular growth induced by VEGF plasmid delivery.

3. Intermittent Claudication: The clinical trial NCT00080392 explores the use of EW-A-401, a VEGF-based therapy, for intermittent claudication—a condition causing pain due to inadequate blood flow during exercise. The phase 1 trial has been completed, suggesting initial investigations into safety and efficacy.

4. No-option Coronary Artery Disease (CAD): The trial NCT00620217 investigated VEGF-A165/bFGF plasmids in patients with no available options for traditional revascularization therapies. This phase 2 trial indicates a controlled exploration of VEGF/bFGF plasmid efficiency in inducing angiogenesis to potentially restore blood supply to the heart.

5. Bone Regeneration: VEGF plasmids have also been studied in the context of bone regeneration. Trials such as NCT06365307 and NCT03076138 examined the use of gene-activated bone substitutes in spinal and maxillofacial bone regeneration, respectively, highlighting their potential in surgical orthopedic applications.

The evidence supports various experimental and early-phase clinical applications of VEGF plasmids in enhancing angiogenesis and tissue repair, though further research is necessary to establish broader efficacy and safety for routine clinical use.

Disclaimer: This content is for informational purposes only and not intended as medical advice. Please consult a healthcare professional for personalized medical guidance.

Safety Profile of VEGF Plasmid Therapy

Known Side Effects:

The available evidence provides limited specific details on the side effects of VEGF plasmid therapy. However, based on general knowledge of gene therapies and VEGF's role in angiogenesis, potential side effects could include inflammation or immune response at the delivery site. More specific studies are needed to establish a comprehensive list of side effects.

Contraindications:

There is insufficient evidence from the provided sources to definitively list contraindications for VEGF plasmid therapy. Generally, gene therapies may not be recommended for individuals with certain immune deficiencies or autoimmune disorders, but further specific studies are needed.

Drug Interactions:

The evidence does not provide detailed information on drug interactions involving VEGF plasmid therapy. Interactions may be influenced by the delivery system or other concurrent treatments targeting angiogenesis. It's crucial to monitor for interactions in clinical settings, particularly with other pro-angiogenic or anti-angiogenic therapies.

Populations to Avoid:

Without specific studies addressing this, it is challenging to identify populations that should completely avoid VEGF plasmid therapy. Caution is generally warranted in populations such as pregnant individuals, children, and those with a history of cancer, due to VEGF's role in cell growth and angiogenesis. Further research is needed to provide explicit guidance.

Evidence Limitations:

The current evidence from the provided sources is inadequate to fully outline the safety profile of VEGF plasmid therapy, highlighting a need for further specific clinical studies.

---

Disclaimer: This information is for educational purposes only and should not be used as a substitute for professional medical advice. Always consult a healthcare provider regarding medical decisions.

Papers on VEGF Plasmid

Research on VEGF plasmids has explored their potential in various therapeutic areas, primarily focusing on angiogenesis and bone healing.

1. Bone-Targeted Delivery for Osteoporosis: A study published in the International Journal of Pharmaceutics examined the use of GLG1-modified PLGA nanoparticles to deliver VEGF and BMP2 plasmids for osteoporosis therapy. The use of these plasmids aimed to enhance bone regeneration, although specifics on the study's sample size or results were not detailed.

2. Gene Delivery Systems: The journal Biomedical Materials reported on the development of core-shell fibrous threads for sustained VEGF plasmid delivery. These threads offer controlled gene release, potentially improving therapeutic outcomes in regenerative medicine. Again, detailed outcomes or sample specifics were not available.

3. Angiogenic Gene Therapy for Ischemia: In a review published in Cells, researchers discussed advancements in angiogenic gene therapy for treating lower extremity ischemia. VEGF plasmids play a critical role in promoting blood vessel growth, although specific study designs or sizes were not mentioned.

4. Polymeric Gene Delivery in Oncogenic Pathways: An article in ACS Biomaterials Science & Engineering explored polymeric gene delivery systems targeting cancer pathways. While not exclusively focused on VEGF, these systems can include VEGF plasmids as part of broader therapeutic strategies.

Overall, these studies highlight the diverse potential applications of VEGF plasmids, though specific clinical outcomes frequently remain insufficiently detailed. More extensive trials could provide clearer evidence of their efficacy and safety in various medical conditions.

Disclaimer

This summary is for informational purposes only and does not constitute medical advice. For personalized medical guidance, please consult a healthcare professional.

Research on VEGF plasmid therapy is actively exploring various dosing and administration protocols. While specific studies focusing solely on VEGF plasmid dosing are limited, some insights can be gathered from related research and clinical trials.

1. Bone-targeted delivery:

   • Study: Bone-targeted delivery using GLG1-modified PLGA nanoparticles reported in the International Journal of Pharmaceutics emphasizes modified delivery systems for targeted therapy, but specific dosing details were not provided.

2. Gene delivery systems:

   • Study: Core-shell fibrous threads loaded with VEGF plasmid polyplexes, mentioned in Biomedical Materials, explore sustained gene delivery. The research focuses on delivery mechanisms rather than exact dosing amounts.

3. Clinical Trials:

   • Trial NCT00620217 evaluated the use of VEGF-A165/bFGF plasmid delivered percutaneously for angiogenesis. While completed, specific dosage was not disclosed in the brief.

4. Experimental Therapies:

   • Title: Angiogenic Gene Therapy for Lower Extremity Ischemia in the Cells journal discusses experimental angiogenic therapies, suggesting ongoing research in delivery methods.

Overall, detailed dosing protocols are not explicitly detailed in the available literature, indicating a focus on the delivery mechanisms and therapeutic effects rather than standardized dosing guidelines.

Disclaimer: This information is for educational purposes only and not intended as medical advice. Always consult a healthcare professional for medical decisions.

The literature on VEGF plasmid therapy presents varied outcomes, primarily focusing on angiogenesis and bone regeneration.

1. Bone Regeneration and Osteoporosis:

   • A study titled "Bone-targeted delivery of VEGF/BMP2 plasmids using GLG1-modified PLGA nanoparticles" explored this therapy for osteoporosis. It reported improvements in bone growth due to enhanced angiogenesis. However, details on specific biomarker changes or symptom improvement were not extensively detailed, suggesting moderate evidence strength.

2. Gene Delivery and Sustained Therapy:

   • Another study, "Core-shell fibrous threads loaded with VEGF plasmid polyplexes," observed that sustained delivery of VEGF plasmids could be achieved. This method may increase efficacy in therapeutic angiogenesis, although it primarily focuses on delivery methods rather than direct clinical outcomes.

3. Ischemic Conditions:

   • "Angiogenic Gene Therapy for Lower Extremity Ischemia" reported experimental advances that include the use of VEGF plasmids to enhance blood vessel formation in ischemic tissues. The evidence is promising but remains in early stages, lacking detailed clinical outcomes.

4. Clinical Trials:

   • Completed trials such as NCT00080392 and NCT00620217 focused on conditions like intermittent claudication and coronary artery disease. The phase 2 trial on no-option CAD patients (NCT00620217) evaluated angiogenesis via VEGF-A165/bFGF plasmid delivery, showing potential in enhancing blood flow, but comprehensive data on long-term outcomes and safety remain limited.

Overall, the evidence indicates potential benefits of VEGF plasmid therapy in promoting angiogenesis and aiding in tissue regeneration. However, detailed and robust clinical outcomes remain sparse, requiring further investigation.

Disclaimer: This information is for educational purposes only and not intended as medical advice. Always consult a healthcare professional for medical concerns.